This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
® (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced that Galt Medical (a wholly-owned subsidiary of Theragenics), partnering with Health Line International Corporation (Health Line), launched the Synergy™ peripherally inserted central catheter (PICC) product line. The product line features Galt’s industry-leading introducer components and Health Line’s Synergy™ PICC line. The Synergy™ expands Galt Medical’s product offering to include implantable delivery devices.
Synergy™ is a power injectable PICC available in sizes from 4-6 French, and in single, dual, and triple lumen configurations. PICC’s are used in treatments requiring vascular access, such as drug therapies, renal therapies, and blood sampling. They are capable of injecting contrast media needed for computed tomography (CT) scans, which eliminates the need for the insertion of a second venous access device. Galt has partnered with Health Line to co-brand and market the Synergy™ PICC in the United States using Galt’s distribution network. The addressable market in the United States for PICC’s is projected to grow at a compound annual growth of 5% and reach $300 million in annual sales by 2015
1. The Synergy is expected to add approximately $150,000 of revenue for Theragenics within the first twelve months of launch.